Your browser doesn't support javascript.
loading
Regulatory T-cell dysfunctions are associated with increase in tumor necrosis factor α in autoimmune hemolytic anemia and participate in Th17 polarization.
Ciudad, Marion; Ouandji, Sethi; Lamarthée, Baptiste; Cladière, Claudie; Ghesquière, Thibault; Nivet, Martin; Thébault, Marine; Boidot, Romain; Soudry-Faure, Agnès; Chevrier, Sandy; Richard, Corentin; Maillet, Thibault; Maurier, François; Greigert, Hélène; Genet, Coraline; Ramon, André; Trad, Malika; Predan, Valérie; Saas, Philippe; Samson, Maxime; Bonnotte, Bernard; Audia, Sylvain.
Affiliation
  • Ciudad M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Ouandji S; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Lamarthée B; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Cladière C; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Ghesquière T; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Nivet M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Thébault M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Boidot R; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
  • Soudry-Faure A; Department of Clinical Research and Innovation (DRCI), Clinical Research Unit-Methodological Support Network (USMR), Dijon Bourgogne University Hospital, Dijon.
  • Chevrier S; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
  • Richard C; Unit of Molecular Biology, Georges-François Leclerc Cancer Center - F-21000 Dijon.
  • Maillet T; Department of Internal Medicine - Centre Hospitalier de Mâcon, Groupe Hospitalier Bourgogne Méridionale - F-71000 Macon.
  • Maurier F; Department of Internal Medicine, Groupe Hospitalier UNEOS - F-57000 Metz.
  • Greigert H; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Genet C; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Ramon A; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Trad M; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Predan V; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon.
  • Saas P; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Samson M; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Bonnotte B; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon.
  • Audia S; Department of Internal Medicine and Clinical Immunology, Referral Center for adult autoimmune cytopenia (CeReCAI) - Dijon University Hospital - F-21000 Dijon, France; Université de Bourgogne, INSERM, UMR1098, RIGHT -F-21000 Dijon. sylvain.audia@u-bourgogne.fr.
Haematologica ; 109(2): 444-457, 2024 Feb 01.
Article in En | MEDLINE | ID: mdl-37534543
ABSTRACT
Warm autoimmune hemolytic anemia (wAIHA) is a rare acquired autoimmune disease mediated by antibodies targeting red blood cells. The involvement of CD4 T-helper cells has been scarcely explored, with most findings extrapolated from animal models. Here, we performed quantification of both effector T lymphocytes (Teff) and regulatory T cells (Treg), associated with functional and transcriptomic analyses of Treg in human wAIHA. We observed a shift of Teff toward a Th17 polarization concordant with an increase in serum interleukin-17 concentration that correlates with red blood cell destruction parameters, namely lactate dehydrogenase and bilirubin levels. A decrease in circulating Treg, notably effector Treg, associated with a functional deficiency, as represented by their decrease capability to inhibit Teff proliferation, were also observed. Treg deficiency was associated with a reduced expression of Foxp3, the master transcription factor known to maintain the Treg phenotype stability and suppressive functions. Transcriptomic profiling of Treg revealed activation of the tumor necrosis facto (TNF)-α pathway, which was linked to increased serum TNF-α concentrations that were twice as high as in controls. Treg transcriptomic profiling also suggested that post-translational mechanisms possibly accounted for Foxp3 downregulation and Treg dysfunctions. Since TNF-α participates in the rupture of immune tolerance during wAIHA, its inhibition could be of interest. To this end, the effects of fostamatinib, a SYK inhibitor, were investigated in vitro, and we showed that besides the inhibition of erythrocyte phagocytosis by monocytes, fostamatinib is also able to dampen TNF-α production, thus appearing as a promising multitargeting therapy in wAIHA (clinicaltrials gov. Identifier NCT02158195).
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Morpholines / T-Lymphocytes, Regulatory / Aminopyridines / Anemia, Hemolytic, Autoimmune Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Haematologica Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Morpholines / T-Lymphocytes, Regulatory / Aminopyridines / Anemia, Hemolytic, Autoimmune Type of study: Prognostic_studies / Risk_factors_studies Limits: Animals / Humans Language: En Journal: Haematologica Year: 2024 Document type: Article
...